Find clinical trials

This study is designed to evaluate the effect of povorcitinib on itch and skin lesions in participants with Prurigo Nodularis. Participants receive either trial medication or a placebo (something that looks like the trial drug but has no effect on the body), both taken orally. The treatment period will approximately be 13 months including safety follow up.

A randomised control clinical trial to explore whether patients with AF-induced cardiomyopathy undergoing catheter ablation can avoid anti-heart failure pharmacotherapy. Patients will be randomised to receive anti-heart failure pharmacotherapy (control) versus monitoring without anti-heart failure pharmacotherapy (intervention). The primary outcome will be change in left ventricular ejection fraction from baseline.

This clinical study is testing a new medication, VH4524184, to see if it can effectively treat HIV-1 in adults who have never received treatment for their infection. The study is comparing two different doses of VH4524184, each taken with the medications emtricitabine and tenofovir alafenamide (FTC/TAF), to a standard HIV treatment called dolutegravir and lamivudine (DTG/3TC). The purpose of the study is to provide data on the long-term antiviral activity of the VH4524184 and provide information regarding dosing formulation for further evaluations. 

The purpose of this study is to investigate the safety and effectiveness of IPN10200, in participants living with migraines. The information gathered from this study will contribute to our understanding of how this study treatment may benefit individuals suffering from migraines. Participants will be assigned the study drug or placebo. Following the confirmation of safety in Step 1 by the DMC, up to two doses of IPN10200 will be compared against placebo in parallel groups in Step 2. 
Participants who meet all study criteria will be randomly assigned to one of three intervention groups: Dose A, Dose B or a placebo. Each participant will be in the study for 40 to 44 weeks including a screening period of 6 weeks (± 2 weeks).
Participants who fulfill all study criteria, will be included and will receive the study treatment at Day 1 (D1), followed by a follow up period of 36 weeks. All the participants will have to attend 7 onsite visits during the study including Screening visit, Day 1, and follow up visits at study site. Participants will also have remote visits (about 7 phone calls in total).